PARSIPPANY, N.J., Jan. 11,
2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI),
a leading specialty pharmaceutical company, today announced that it
will host an Investor Meeting on January 25,
2013 in New York. The
meeting will begin at 8:00 a.m. EST
and will be webcast simultaneously.
The meeting will be hosted by Watson's executive leadership team and will
offer an in-depth look into the combined company following the
acquisition of the Actavis Group.
Paul Bisaro, Watson's President and CEO, will provide a
review of 2012 and the forecast for growth in 2013 and beyond.
Todd Joyce, Watson's Chief
Financial Officer, will provide a detailed review of financials,
including an update on how the new company will report, expected
synergies, the company's foreign exchange and tax positions and
plan for deleveraging. Siggi
Olafsson, President, Global Generics, will provide a
detailed look at Watson's expanded
global generics business that now spans more than 60
countries.
Fred Wilkinson, President, Global
Brands, will offer insight into Watson's brands and biologics businesses — key
growth drivers for the company's future — including an update on
the brand pipeline, and Bob Stewart,
President, Global Operations, will provide an update on
Watson's expanded global supply
chain.
In-person attendance at the meeting is by invitation only.
The webcast will be available live to investors and the media
on Watson's Web site or at the
following link:
http://www.videonewswire.com/event.asp?id=91366.
A replay of the webcast will be available approximately two
hours following the completion of the event on the Company's Web
site.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global,
integrated specialty pharmaceutical company focused on developing,
manufacturing and distributing generic, brand and biosimilar
products. The Company has global and U.S. headquarters in
Parsippany, New Jersey, USA, and
international headquarters in Zug, Switzerland.
Watson is the world's
third-largest generics prescription drug manufacturer, with more
than 750 products marketed globally through operations in more than
60 countries. Watson's
global branded pharmaceutical business develops and markets
products principally in Urology and Women's Health, and
is committed to developing and marketing biosimilars products
in Women's Health, Oncology and other therapeutic categories.
In addition, Watson is the
fourth-largest U.S. generic pharmaceutical product distributor
through its Anda, Inc. business, and also develops and out-licenses
generic pharmaceutical products outside of the U.S. through its
Medis third-party business. Watson has announced that it will
adopt a new global name – Actavis – effective in 2013.
For press release and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watson.com.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Media:
Charlie Mayr
(862) 261-8030
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO
)
SOURCE Watson Pharmaceuticals, Inc.